12 results for "Transplant"

Liver Transplant - A Prospective, Observational Study of Donor and Recipient Factors

This study is intended to evaluate if there is injury to the liver in liver transplant patients.

Liver Transplantation and the effect of the OrganOx metra® device vs standard care

The OrganOx metra® device may be a new way of storing (preserving) the liver prior to transplantation. Currently this machine is only intended for investigational use and is not commercially available in the United States. The device uses a method to store the liver at normal body temperature during transport after it has been removed from the donor. The goal is to determine if this method may improve the outcome of transplant over the traditional “cold storage” method.

Observational Study to evaluate patients receiving Transarterial Chemoembolization (TACE) Therapy

The purpose of this study is to determine if there is a link between liver cancer recurrences after liver transplant, in a specific population of patients who have received TACE therapy.

BMT CTN 1503: Bone Marrow Transplantation vs SOC for Severe Sickle Cell Disease (STRIDE2)

This is a clinical trial that will compare survival and sickle related outcomes in adolescents and young adults with severe sickle cell disease after bone marrow transplantation and standard of care. The primary outcome is 2-year overall survival.

Click here to download the Fast Facts


The objective of the study is to evaluate whether the 50cc TAH-t can safely support, and provide probably benefit to, transplant-eligible pediatric patients (aged 10-18 years) and adult patients (aged 19-75 years) at imminent risks of death from biventricular failure without experiencing permanent disabling, stroke-related deficits.

Recurrent Primary Sclerosing Cholangitis and the effects of Vancomycin

This study is testing the use of an antibiotic called Vancomycin to treat the recurrence of primary sclerosing cholangitis in liver transplant patients.

Barostim Therapy for Heart Failure (BeAT-HF)

The objective of this study is to demonstrate that treatment with the Barostim neo system, relative to medical management, reduces the rate of cardiovascular mortality or worsening heart failure that leads to hospitalization, cardiac assist device or heart transplant.

JAZZ 201: Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

This is a study comparing the Defibrotide prophylaxis arm vs standard of care arm for the prevention of aGvHD.

Click here to download the Fast Facts

E1910: BCR-ABL Negative B Lineage ALL and the Effects of Blinatumomab

This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as blinatumomab, may block cancer growth in different ways by targeting certain cells. It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.

Click here to download the Fast Facts

Heart Failure and the effects of the OPTIMIZER® System

Evaluation of the Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure With Ejection Fraction Between 25% and 45%: FIX-HF-5C

**This study is not accepting new participants at this time.

Respond CAS

The objective of the Continued Access study is to gather confirmatory evidence on the safety of the SonRtip lead and performance of the automatic atrioventricular (AV) delay and interventricular (VV) delay optimization algorithm used in the PARADYM RF SONR Cardiac Resynchronization Therapy with Defibrillation (CRT-D) device (Model 9770) in a patient population that is reflective of current heart failure treatment practice.


This trial is testing that intensive medical management differs from the combination of CEA and intensive medical management in preventing the primary endpoint in patients with high-grade asymptomatic carotid stenosis and to test that intensive medical management differs from the combination of CAS and intensive medical management in preventing the primary endpoint in patients with high-grade asymptomatic carotid stenosis.